Aims: To evaluate diabetic retinopathy (DR) data from across the SUSTAIN clinical trial programme.
| INTRODUCTION
Semaglutide is a glucagon-like peptide-1 (GLP-1) analogue, with an extended half-life of~1 week, that is in development for the treatment of type 2 diabetes (T2D). 1, 2 The efficacy and safety of semaglutide has been evaluated in the Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes (SUSTAIN) clinical trial programme, including five global trials (SUSTAIN 1-5), two Japanese trials and one pre-approval cardiovascular (CV) outcomes trial (SUSTAIN 6), and covers the continuum of T2D care. Semaglutide treatment led to significant and sustained improvements in glycated haemoglobin (HbA1c) and body weight vs placebo and active comparators across the SUSTAIN programme. [3] [4] [5] [6] [7] [8] In SUSTAIN 6, semaglutide demonstrated a significant 26% risk reduction for the primary composite CV outcome vs placebo at 2 years. 8 Microvascular complications were evaluated as a secondary endpoint; a significantly lower risk of new or worsening nephropathy was reported with semaglutide vs placebo (hazard ratio [HR] 0.64, 95% confidence interval [CI] 0.46-0.88; P = .005); however, semaglutide was associated with a higher rate of diabetic retinopathy complications (DRC) vs placebo (HR 1.76; 95% CI 1.11-2.78; P = .02). 8 Risk factors for the development and progression of diabetic retinopathy (DR) include poor glycaemic control, long duration of diabetes and poorly controlled blood pressure. 9 The beneficial effect of long-term, stringent glycaemic control on the prevention or delay in onset or progression of DR in patients with type 1 diabetes and T2D
is established [10] [11] [12] ; however, large and rapid improvements in glycaemic control may be associated with a transient worsening of DR, which in the long term can be counterbalanced by reduction in DR with improved glycaemia. 11, 13 Risk factors for DR are well recognized and should be monitored and managed in accordance with existing guidelines. 14 In the present paper, we present how DR was evaluated, and the results obtained, across the full clinical development programme for semaglutide. Additionally, we present new analyses that provide further insights into the DRC findings from SUSTAIN 6.
| MATERIALS AND METHODS
The SUSTAIN 1 to 5 and Japanese trials assessed the efficacy and safety of subcutaneous, once-weekly semaglutide (0.5; 1.0 mg) vs placebo or active comparators in adult populations with T2D, ranging from treatment-naïve patients to those treated with insulin (Table S1) . [3] [4] [5] [6] [7] [8] In the SUSTAIN 1 to 5 and Japanese trials, known proliferative retinopathy or maculopathy requiring acute treatment, according to the opinion of the investigator, were exclusion criteria, and the upper limit of HbA1c was 10% or 10.5%. SUSTAIN 6 was a 2-year CV outcomes trial, designed to assess the CV safety of once-weekly semaglutide (0.5; 1.0 mg) vs volumematched placebo, as an add-on to standard of care. 8 The primary comparison was pooled semaglutide vs pooled placebo. Secondary microvascular outcomes included new or worsening nephropathy and DRC, both based on external event adjudication committee (EAC)-confirmed events. The trial enrolled 3297 patients who, in contrast to the SUSTAIN 1 to 5 and Japanese trials, represented a population with advanced T2D and high CV risk. 8 Importantly, there were no inclusion/exclusion criteria related to DR, and no upper limit for HbA1c.
| Assessment of DR across the SUSTAIN clinical trial programme
Data collection on DR (Table S2) included medical history, adverse event (AE) reporting, EAC-confirmed DRC (SUSTAIN 6 only) and fundoscopy or fundus photography. In SUSTAIN 6, fundoscopy/fundus photography was also performed at weeks 56 and 104 (planned end of treatment), or after premature discontinuation of treatment, and in the Japanese trials it was also performed at the planned end of treatment. Fundoscopy/fundus photography could be performed by the investigator, local ophthalmologist or optometrist according to local practice; however, no record of who performed the examinations or the type of assessment performed was kept. Furthermore, dilation of the pupil during these assessments was not mandatory, and thus not recorded, and fundus photographs were not centrally graded. Findings were categorized, as per the protocol, by the investigator as "normal," "abnormal, not clinically significant," or "abnormal, clinically significant." Fundoscopic data from SUSTAIN 1 to 5 and the Japanese trials are not presented.
| Medical history

| AE reporting
Diabetic retinopathy AEs were collected as part of the standard safety reporting of AEs in all SUSTAIN clinical trials.
| EAC-confirmed DRC (SUSTAIN 6)
Time to first event of DRC was a secondary endpoint measured in Criteria were not mutually exclusive; simultaneous fulfilment of more than one of the criteria was considered a single event for the DRC endpoint.
Adjudication of DRC was performed by an external EAC, comprising two independent ophthalmologists, who were masked to treatment (Supporting Information, File S1).
Further information was requested from the sites by Novo Nordisk after the trial completion regarding the EAC-confirmed blindness cases. 3 | RESULTS
|
| Baseline characteristics
The baseline characteristics of patients in SUSTAIN 1 to 5 and Japanese trials vs SUSTAIN 6 are described in Table 1 . The proportion of patients with DR at baseline in the SUSTAIN 1 to 5 and Japanese trials was 3.7% to 14.5%. In SUSTAIN 6, 29.4% of the trial population had known, pre-existing DR at baseline (semaglutide, 30.9%; placebo, 27.8%), and there were similar numbers of patients with proliferative DR at baseline in both treatment groups (semaglutide, 6.3%; placebo, 6.0%; Table S3 ).
| Diabetic retinopathy AEs
The DR AEs reported in the SUSTAIN 1 to 5 and Japanese trials were balanced across treatments, all events were mild or moderate and there were no serious AEs (Table 2 ). In SUSTAIN 6, a greater proportion of AEs was reported in semaglutide-vs placebo-treated patients. Comparators N = 1657 The majority of AEs were mild or moderate; few were reported as serious AEs (Table 2 ).
| DRC in SUSTAIN 6
More (Table S4 ). Although 79 patients had DRC, there were 98 events in total, as some patients had more than one event (Supporting Information, File S1 and Table S4 ).
| Baseline characteristics of patients with DRC
Compared with the overall trial population, patients with EACconfirmed DRC were characterized by pre-existing DR, a longer mean diabetes duration, higher mean HbA1c levels at baseline and greater proportions of patients receiving insulin treatment at trial entry (Table S3) .
A greater proportion of patients with DRC had pre-existing DR Table S3 and Figure 1A ). For semaglutide-treated patients with no known pre-existing DR at baseline, the risk of DRC was low and there was no statistically significant difference vs placebo (Table S3 and Figure 1B) ; the number (proportion) of patients with no preexisting DR at baseline who developed an event was 5 (10.0%) for semaglutide and 4 (13.8%) for placebo. Overall, a higher risk for DRC with semaglutide vs placebo was observed in patients with proliferative and non-proliferative DR at baseline ( Figure S1 ). There was no evidence of a dose-dependent effect on DRC with semaglutide (Figure S2): 25 patients in each dose group had an event.
In patients with pre-existing DR at baseline, the risk of DRC was further increased in patients treated with insulin prior to the event ( Figure 1C,D) . No increase in risk was associated with prior insulin use in patients without known pre-existing DR at baseline.
| Glycaemic control
Semaglutide-treated patients experienced significant and sustained reductions in HbA1c from baseline vs placebo in the overall trial population (Figure 2A,B) . 8 The reduction in HbA1c with semaglutide vs placebo in patients with DRC was 1.9% and 2.5% at week 16 with semaglutide 0.5 and 1.0 mg, respectively, vs 0.9% and 1.3% with placebo 0.5 and 1.0 mg ( Figure 2C ) and reductions in HbA1c were greater vs the overall trial population until the end of the trial (week 104, Figure 2D) . A similar pattern for the incidence rate of DRC with semaglutide or placebo was seen in patients with pre-existing DR, when stratified according to change in HbA1c by week 16. The incidence rate of confirmed events was highest in patients with HbA1c
reductions >1.5% with semaglutide or placebo (Figure 3) . In patients without pre-existing DR, the incidence rate of DRC was low and similar between treatment groups, regardless of the magnitude of HbA1c reduction ( Figure 3A) .
A post hoc mediation analysis showed that when controlling for HbA1c reduction at week 16, for semaglutide vs placebo, the HR for DRC is reduced to 1.22 (95% CI 0.71-2.09; P = .48; Figure 2E) ; therefore, the majority of the treatment effect could be attributed to the reduction in HbA1c at week 16. Expansion of the mediation analysis to include other baseline variables did not change the mediator analysis results (Supporting Information, File S3).
| Blood pressure control
Additional post hoc analyses were performed to assess the role of blood pressure control in the DRC finding; however, there was no indication of an effect (Supporting Information, File S3).
| Events evaluated as diabetes-related blindness in SUSTAIN 6
In total, the EAC evaluated that 6 patients met the criteria for events of diabetes-related blindness: 5 with semaglutide; 1 with placebo (Table S5 ). All 5 semaglutide-treated patients had pre-existing proliferative DR and other eye diseases (eg, cataract), and all had received treatment with laser therapy and/or intravitreal agents prior to entering the trial. The placebo-treated patient with diabetes-related blindness had no known pre-existing DR.
Further information was available for 3 of the 5 semaglutidetreated patients post event, none of whom continued to fulfill the criteria for diabetes-related blindness (2 patients 18 months post event, and 1 patient, 21 days post event). Table S6 shows fundoscopy/fundus photograph assessments at baseline and end of treatment. After 2 years, the proportion of patients in each category was similar in the two treatment arms.
| Fundoscopy/fundus photographs in SUSTAIN 6
| DISCUSSION
The SUSTAIN clinical trial programme was designed to evaluate the efficacy and safety of semaglutide across the continuum in patients with T2D; the trials were not specifically designed to investigate DR. Although there was no increase in DR AEs in the SUSTAIN 1 to 5 or Japanese trials with semaglutide vs comparators, there was a significant 76% increase in the risk of DRC with semaglutide vs placebo in SUSTAIN 6.
8
The increased risk of DRC in SUSTAIN 6 was identified using a dichotomous secondary endpoint, thus only allowing the identification of predetermined events, and the trial design does not provide a sensitive assessment of progression of retinal changes over time. 
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Week 16 Overall trial population Patients with DRC FIGURE 2 Glycated haemoglobin (HbA1c) in SUSTAIN 6: Change in HbA1c over time and from baseline to week 104 in the overall population (A and B); change in HbA1c over time and from baseline to week 104 in subjects with diabetic retinopathy complications (DRC; C and D); Post hoc mediation analysis of the effect of change in HbA1c (%) at week 16 for time to first (external) event adjudication committee (EAC)-confirmed DRC (E). Overall trial population, n = 3297; patients with DRC, n = 79. Values are estimated means (AE SE) from a mixed model for repeated measurements analysis using "in-trial" data from patients in the full analysis set. The table summarizes the results of a post hoc mediation analysis for time to first EAC-confirmed DRC, together with the results of the prespecified analysis. The mediation analysis assesses the effect of change in HbA1c at week 16 on time to first DRC. This is analysed by an unstratified Cox proportional hazards model, which in addition to treatment (semaglutide, placebo) as a fixed factor also includes "change in HbA1c (% points) at week 16" as a covariate as well as confounding variables "HbA1c at baseline," "retinopathy at baseline" ("yes," "no," "unknown/missing") and "baseline duration of diabetes." Variables were deemed to be confounding if they were significantly associated with both a change in HbA1c at week 16 and time to first retinopathy complications. This was analysed by use of separate univariate ANCOVAs and Cox proportional hazards models. Other considered confounders were "gender" and "body weight" at baseline. Missing values of HbA1c were imputed as predicted values from a mixed model for repeated measurements. "Proportion eliminated" is calculated as: (total effect of treatment − controlled direct effect of treatment)/(total effect of treatment −1); ie, the absolute risk reduction from the mediation analysis divided by the total excess risk. Rapid and marked reductions in HbA1c, as a result of improved glycaemic control initiated during pregnancy, bariatric surgery or intensified insulin treatment, have previously been associated with transitory worsening of DR 11, 12, [15] [16] [17] [18] [19] ; this has also been reported in patients with type 1 diabetes in the Diabetes Control and Complications Trial (DCCT), 12 and in newly diagnosed patients with T2D in the UK Prospective Diabetes Study (UKPDS 33). 11 It is important to note that the DCCT excluded patients with proliferative retinopathy, and used a more sensitive assessment method with graded retinal imaging to chart the progression of DR. 12 Although the characteristics of patients in the DCCT are different from those in SUSTAIN 6, the increased risk of DRC may be a manifestation of an "early worsening" phenomenon attributable to the large and rapid reduction in HbA1c.
Consequently, patient profiling and risk assessment before intensification of treatment may help identify patients whose eyes require close monitoring.
Other agents causing abrupt glycaemic improvement (eg, insulin) have warnings in their prescribing information about the potential association with temporary worsening of DR. 20 In the insulin glargine clinical development programme, more frequent DR progression was reported with insulin glargine vs NPH in patients with T2D; 21 however, a subsequent 5-year DR trial, employing 7-field Early Treatment
Diabetic Retinopathy Study fundus photographic assessment, showed no detrimental effect with insulin glargine vs NPH on the long-term progression of DR. Limited data are available regarding DR with GLP-1 receptor agonists. In the LEADER trial, the CV outcomes trial of liraglutide, the HR for the DRC endpoint disfavoured liraglutide, although the difference was not significant (HR 1.15; 95% CI 0.87-1.52; P = .33). 23 With exenatide, a retrospective analysis of patients receiving treatment twice daily for longer than 6 months, showed that DR had progressed in 30% of patients and progression of DR was associated with greater reductions in HbA1c; there was no comparator. 24 In the same group of patients, DR had improved or remained stable after follow-up, suggesting that early worsening did not progress. 25 With albiglutide, a higher incidence of on-therapy DR AEs was reported vs placebo (3.6% vs 1.7%), but not with comparators. 26 Importantly, only one of these studies applied robust methods for assessing DR prospectively 25 ; whereas the majority of the DR findings relating to GLP-1 receptor agonists were based on standard AE reporting and not reti- The increased risk of DRC with semaglutide vs placebo in patients with poor glycaemic control and pre-existing DR in SUSTAIN 6 must be viewed in the wider context of the overall benefits with semaglutide treatment, including reduction in HbA1c, body weight and CV risk reduction. 8 The beneficial effect of intensive glycaemic control on microvascular outcomes in the long term is well described, and optimization of FIGURE 3 Incidence of diabetic retinopathy complications (DRC) in SUSTAIN 6 by baseline diabetic retinopathy (DR) and glycated haemoglobin (HbA1c) reduction: patients without baseline DR (A); patients with known pre-existing DR (B). Values are observed incidence rates per 100 patient-years of risk (PYR) with error bars representing 95% confidence intervals (CIs). A patient's risk time is defined as the time from randomization to first event or censoring glycaemic control remains the cornerstone of diabetes management and the prevention, or prevention of progression, of microvascular diseases such as DR and nephropathy. Improved glycaemic control had a beneficial effect on DR in both the DCCT and the UKPDS in the long term, and the magnitude of benefit on the risk of DR continued to increase over time, and was more pronounced in patients with DR at baseline. 11, 12 Although fundoscopic assessments were collected in SUSTAIN 6, there are significant limitations to the granularity of these data, and it is necessary to interpret them with caution. However, they do provide reassurance that the retinal changes observed with semaglutide are similar to those seen with placebo at the end of treatment.
Furthermore, events that the EAC evaluated as "onset of diabetes- 
